| External factors: | Avenanthramide A |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Colorectal cancer |
| Experiment: | SA-β-gal activity assay//Western blot |
| Description: | The mice in AOM/DSS group showed a high tumor burden in colon tissues, while AVN A treatment obviously suppressed AOM/DSS induced tumors. The proportion of cells with senescent cell morphology and SA-β-gal staining were increased in dose and time-dependent manner after exposed to indicated concentration of AVN A for 3, 5 or 7 days. The protein level of p21 increased in a dose-dependent manner when treated with AVN A for 3 days. |
| Regulatory pathway: | miR-129-3p-Pirh2-p53 |
| R-EF-Pathway: | Activation |
| Pathway experiment: | Western blot//qRT-PCR |
| Pathway description: | AVN A treatment significantly elevated miR-129-3p expression in a dose-dependent manner. Overexpression of miR-129-3p dramatically suppressed mRNA level of Pirh2 in CRC cells, which was in agreement with our observations that AVN A treatment dramatically decreased the Pirh2 mRNA level .Moreover, western blot analysis also confirmed that the expression of Pirh2 was downregulated in miR-129-3p overexpressing cells. |
Annotation: